46610 Federal Register / Vol. 74, No. 174 / Thursday, September 10, 2009 / Notices 

notify interested persons regarding their 

request to speak by October 8, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact AnnMarie 

Williams, Conference Management 

Staff, 301–796–5966, at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 4, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–21810 Filed 9–9–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Amendment—Public Meeting 

of the AHRQ National Advisory Council 

for Healthcare Research and Quality 

Subcommittee On Quality Measures 

for Children’s Healthcare in Medicaid 

and Children’s Health Insurance 

Programs 

With this correction notice, the 

Agency for Healthcare Research and 

Quality (AHRQ) informs public of an 

Amendment made to the notice subject 

mentioned above which was published 

on August 20, 2009, Vol. 74, No. 160, 

pages 42079–42080, The amendment is 

to add at the end of section 

SUPPLEMENTARY INFORMATION, the 

following: ‘‘As previously noted, the 

meeting is open to the public and can 

also be joined via Webcast. The link to 

online registration for Webcast is 

http://www.ConnectLive.com/events/ 

AHRQ2009.’’ 

Dated: September 3, 2009. 

Carolyn M. Clancy, 

Director. 

[FR Doc. E9–21690 Filed 9–9–09; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Ethics Subcommittee, Advisory 

Committee to the Director, Centers for 

Disease Control and Prevention (CDC) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention announces the 

following Subcommittee meeting: 

Time and Date: 10:30 a.m.–12:30 p.m., 

September 24, 2009. 

Place: The teleconference call will 

originate at the Centers for Disease Control 

and Prevention in Atlanta, Georgia. Please 

see ‘‘Supplementary Information’’ for details 

on accessing the teleconference. 

Status: Open to the public, teleconference 

access limited only by availability of 

telephone ports. The public is welcome to 

participate during the public comment 

period which is tentatively scheduled from 

12:15 p.m.–12:25 p.m. 

Purpose: The Ethics Subcommittee will 

provide counsel to the ACD, CDC, regarding 

a broad range of public health ethics 

questions and issues arising from programs, 

scientists and practitioners. 

Matters To Be Discussed: The 

teleconference agenda will include ethical 

guidance for ventilator distribution during a 

pandemic, update on CDC’s public health 

ethics activities, and follow-up on 

outstanding activities/reports. 

Agenda items are subject to change as 

priorities dictate. 

Supplementary Information: This 

conference call is scheduled to begin at 

10:30 a.m. To participate in the 

teleconference, please dial 1/866/919– 

3560 and enter conference code 

4168828. You will then be automatically 

entered into the call. 

Contact Person for More Information: Drue 

Barrett, PhD, Designated Federal Officer, 

Ethics Subcommittee, CDC, 1600 Clifton 

Road, NE., M/S D–50, Atlanta, Georgia 

30333. Telephone (404/639–4690. E-mail: 

dbarrett@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: September 1, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–21920 Filed 9–9–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Clinical Resources. 

Date: September 28, 2009. 

Time: 10 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817 (Telephone Conference 

Call). 

Contact Person: Wendy F. Davidson, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIH/NIAID/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892–7616, 301– 

402–8399, davidsonw@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–21791 Filed 9–9–09; 8:45 am] 

BILLING CODE 4140–01–P 


erowe on DSK5CLS3C1PROD with NOTICES